1322 related articles for article (PubMed ID: 16764099)
1. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
3. Anti-Alzheimer drugs: life-threatening adverse effects.
Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
[TBL] [Abstract][Full Text] [Related]
4. Cholinesterase inhibitors in the treatment of dementia.
Ellis JM
J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
[TBL] [Abstract][Full Text] [Related]
5. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
[TBL] [Abstract][Full Text] [Related]
6. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
7. Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
Prescrire Int; 2011 Apr; 20(115):95. PubMed ID: 21648211
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
9. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Schölzel-Dorenbos CJ;
Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic management of Alzheimer disease.
Downey D
J Neurosci Nurs; 2008 Feb; 40(1):55-9. PubMed ID: 18330411
[TBL] [Abstract][Full Text] [Related]
13. Drugs for cognitive loss and dementia.
Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
[TBL] [Abstract][Full Text] [Related]
14. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Doody RS
J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
[TBL] [Abstract][Full Text] [Related]
15. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Beier MT
Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
18. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
[TBL] [Abstract][Full Text] [Related]
20. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
